Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure?

JACC Heart Fail. 2014 Dec;2(6):583-5. doi: 10.1016/j.jchf.2014.05.005. Epub 2014 Jul 2.

Authors

Deepak L Bhatt¹, Matthew A Cavender²

Affiliations

¹ TIMI (Thrombolysis in Myocardial Infarction) Study Group, Brigham and Women's Hospital Heart & Vascular Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: DLBHATTMD@post.harvard.edu.
² TIMI (Thrombolysis in Myocardial Infarction) Study Group, Brigham and Women's Hospital Heart & Vascular Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

PMID: 24998081
DOI: 10.1016/j.jchf.2014.05.005

No abstract available

Keywords: diabetes; heart failure; hospitalization; mortality; sitagliptin.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Diabetes Mellitus, Type 2 / drug therapy*
Diabetic Angiopathies / drug therapy*
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use*
Female
Heart Failure / drug therapy*
Humans
Male
Pyrazines / therapeutic use*
Triazoles / therapeutic use*

Substances

Dipeptidyl-Peptidase IV Inhibitors
Pyrazines
Triazoles